AVXL - CIK 0001314052
ANAVEX LIFE SCIENCES CORP. trades as AVXL. This page tracks ANAVEX LIFE SCIENCES CORP. through 584 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Major company event | 8-K | 2026-05-15 |
| New insider ownership | 3 | 2026-05-14 |
| NT 10-Q | - | 2026-05-11 |
| Major company event | 8-K | 2026-05-06 |
| New insider ownership | 3 | 2026-05-01 |
| SCHEDULE 13G/A | - | 2026-03-26 |
| Major company event | 8-K | 2026-03-25 |
The largest companies sharing ANAVEX LIFE SCIENCES CORP.'s SEC industry classification (biological products, (no diagnostic substances)).
In its latest fiscal year ANAVEX LIFE SCIENCES CORP. reported a net loss of $46.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.